1. Once authorship questionnaires have been collected and processed, GSK Vaccines appropriately shares the outcome of the collection process with potential authors:
   - Strongly agree: 27.5% (n=75)
   - Agree: 64.8% (n=162)
   - Neither agree nor disagree: 7.7% (n=21)
   - Disagree: 0.7% (n=2)
   - Strongly disagree: 0.7% (n=2)

2. The timing when the authorship questionnaire is sent out is appropriate:
   - Strongly agree: 24.2% (n=66)
   - Agree: 60.1% (n=164)
   - Neither agree nor disagree: 11.7% (n=32)
   - Disagree: 3.3% (n=9)
   - Strongly disagree: 1.8% (n=5)

3. The format and content of the authorship questionnaire are appropriate to assess authorship eligibility as per ICMJE criteria:
   - Strongly agree: 22.0% (n=60)
   - Agree: 64.8% (n=177)
   - Neither agree nor disagree: 9.5% (n=26)
   - Disagree: 3.3% (n=9)
   - Strongly disagree: 1.8% (n=5)

4. The authorship questionnaire is a helpful tool to gather the respective contributions to a study and to guide future discussions on authorship:
   - Strongly agree: 27.5% (n=75)
   - Agree: 59.3% (n=162)
   - Neither agree nor disagree: 7.7% (n=21)
   - Disagree: 0.7% (n=2)
   - Strongly disagree: 0.7% (n=2)